Gilder Gagnon Howe & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-252,031	Closed	-$4.57M	–	297
2016 Q3	$4.57M	Buy	252,031 +247,322	+5,252%	+$4.83M	0.08%	132
2016 Q2	$78K	Buy	+4,709	New	+$76.2K	﹤0.01%	255
2015 Q4	–	Sell	-61,350	Closed	-$1.22M	–	278
2015 Q3	$1.22M	Sell	61,350 -12,920	-17%	-$408K	0.02%	185
2015 Q2	$2.58M	Sell	74,270 -7,183	-9%	-$219K	0.03%	180
2015 Q1	$2.12M	Buy	+81,453	New	+$1.49M	0.03%	178
2014 Q3	–	Sell	-77,419	Closed	-$1.23M	–	317
2014 Q2	$1.23M	Buy	77,419 +52,580	+212%	+$750K	0.02%	219
2014 Q1	$376K	Buy	+24,839	New	+$281K	0.01%	235

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gilder Gagnon Howe & Co's HZNP Position: Q4 2016 in Review

Gilder Gagnon Howe & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2016, closing a stake of 252,031 shares — an estimated $4.57M sold.

Gilder Gagnon Howe & Co first reported a position in HZNP in Q1 2014 and held it in 7 quarters. The position peaked at $4.57M in Q3 2016. 234 funds tracked by Wall St. Rank hold HZNP as of Q4 2016.

Gilder Gagnon Howe & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2016 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 252,031 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2016, an estimated $4.57M.
Gilder Gagnon Howe & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2014 and held it in 7 quarters.
Gilder Gagnon Howe & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.57M in Q3 2016.
234 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2016.

Based on Gilder Gagnon Howe & Co's 13F filing for Q4 2016, filed 1 Feb 2017.